China Health Group Limited
中國衛生集團有限公司

(Carrying on business in Hong Kong as CHG HS Limited)
(Incorporated in Bermuda with limited liability)
(Stock Code: 673)

UPDATE IN RELATION TO THE DISCLAIMER OF OPINION ON GOING CONCERN SET OUT IN THE ANNUAL REPORT FOR THE YEAR ENDED 31 MARCH 2025

The board of directors of the China Health Group Limited (the "**Company**") wishes to make an update on its actions in resolving the auditors' disclaimer opinion on the consolidated financial statements of the Company for the year ended 31 March 2025 in respect of going concern (the "**Disclaimer of Opinion**").

Reference is made to the annual report of the Company for the year ended 31 March 2025 (the "**Annual Report**") and the announcements dated 19 November 2025 and 23 January 2026 (the "**Announcements**"). Unless the context requires otherwise, capitalised terms used in this announcement shall have the same meaning as defined in the Annual Report.

As set out in the Annual Report, to address the liquidity pressure of the Group and the Disclaimer of Opinion for the year ended 31 March 2026, the Board has been actively implementing several plans and measures, including (i) entering into the subscription agreements to raise estimated gross proceeds of approximately HK$70.0 million; (ii) proposing a rights issue to raise estimated gross proceeds of approximately HK$15.0 million; (iii) negotiating with the bank for renewal of the Group's bank borrowing of approximately HK$5.4 million as at 31 March 2025; and (iv) seeking potential new funding through various channels as and when needed.

As mentioned in the Announcements, the subscriptions and rights issue, as referred to (i) and (ii) above, were completed on 6 October 2025 and raised aggregate net proceeds of approximately HK$80.9 million.

With reference to (iii) above, the Board is pleased to report that the bank borrowing of approximately HK$5.4 million as at 31 March 2025 was fully repaid in February 2026. Subsequently, the Group obtained a new banking facility with a credit limit of approximately HK$4.6 million for a term of two years.

With reference to (iv) above, the Board is pleased to report that the subscription for new shares was completed on 26 February 2026, raising further net proceeds of approximately HK$25,270,000. The Board is continually assessing the Group's operational and funding needs and consider seeking additional financing through various channels, as and when necessary.

The Company will publish further updates on 23 July 2026 until the Disclaimer of Opinion is resolved.

Shareholders and investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
China Health Group Limited
Cao Xu
Chairman of the Board and Executive Director

Hong Kong, 15 May 2026

As of the date of this announcement, the Board comprises three executive Directors, namely, Mr. Cao Xu (Chairman), Mr. Chung Ho and Ms. Ying Rensi; two non-executive Directors, namely, Mr. Ying Wei and Mr. Huang Lianhai; and three independent non-executive Directors, namely, Mr. Li Hongyi, Mr. Wu Hui and Ms. Yang Huimin.